Search bioRxiv⌕ Search

SEARCH · Search bioRxiv

Results for “Cancer Biology”

Search indexed bioRxiv preprints in genomics, neuroscience, cell biology and bioinformatics. Read source abstracts and check manuscript versions; preprints are not peer reviewed.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources

ORBIT: Annotation-Aware Empirical Enrichment and Semantic Reranking for Interpretable Functional-Class Recovery

Gene-set interpretation workflows are widely used to summarize transcriptomic and proteomic experiments, yet standard enrichment tools often return long, redundant result tables that require substantial manual consolidation. We developed ORBIT (Ontology-Ranked Biological Interpretation Tool), an annotation-aware interpretation workflow that combines empirical enrichment, semantic reranking, and redundancy-aware representative-term selection to prioritize interpretable functional summaries from gene sets. We evaluated ORBIT on a curated tiered benchmark of human functional-class gene sets spanning clean reference sets, size-ladder variants, and mixed-difficulty cases. On the 45-set core benchmark, ORBIT semantic achieved higher expected-class recovery than Enrichr and PANTHER Gene Ontology molecular-function baselines, with a mean reciprocal rank of 0.916 and top-1 recovery of 0.889. Bootstrap confidence intervals and paired permutation testing supported the robustness of this advantage, and supplemental analyses extended the comparison to g:Profiler. In a GPCR mixed-function case study, ORBIT compressed redundant enriched terms into semantic representative neighborhoods, illustrating how long enrichment outputs can be converted into reviewable biological summaries. We applied ORBIT across complementary transcriptomic analyses spanning single-cell immune-cell markers, interferon-beta stimulation, and breast-cancer subtype biology. In these settings, ORBIT condensed marker and differential-expression signatures into prioritized functional summaries with explicit links to the genes, cell types, and annotation classes supporting each result. Together, these applications show how ORBIT can move from ranked enrichment terms to structured biological interpretation, preserving the evidence trail from input genes to functional summaries.

bioinformatics↗

Cancer prevalence is remarkably low in turtles and is correlated with life history traits in birds, mammals, and squamates

Identifying species with unusually low cancer prevalence can provide new insights into cancer resistance. Most studies have focused on mammals, but the genetic, physiological, and ecological diversity among vertebrates can influence cancer susceptibility. We used necropsies from over a thousand species of amphibians, birds, crocodilians, mammals, squamates, and turtles to investigate relationships between cancer prevalence, intrinsic cancer risk, body mass, and lifespan. Previous studies often relied on species averages, leading to inaccurate interpretations. Our innovative statistical approach uses raw cancer data and resampling to improve accuracy. We found remarkably low cancer prevalence in turtles, high prevalence in squamates and mammals, and lower-than-expected prevalence based on lifespan and body mass in multiple groups. Our results show lifespan influences neoplasia and malignancy transformation rates in mammals, while body mass affects neoplasia prevalence in amphibians and squamates. These data reveal a complex relationship between life history traits and cancer risk, identifying vertebrates with potential novel cancer resistance mechanisms. STATEMENT OF SIGNIFICANCEBiodiversity is an untapped natural resource for understanding cancer. Our study reveals a wide divergence in cancer prevalence among vertebrate groups, with notably low rates in turtles and high rates in squamates and mammals. These findings can lead to new breakthroughs in understanding the biology of cancer.

evolutionary biology↗

Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR

Autophagy is a biological process that maintains cellular homeostasis and regulates the internal cellular environment. Hyperactivating autophagy to trigger cell death has been a suggested therapeutic strategy for cancer treatment. Mechanistic target of rapamycin (mTOR) is a crucial protein kinase that regulates autophagy; therefore, using a structure-based virtual screen analysis, we identified lomitapide, a cholesterol-lowering drug, as a potential mTOR complex 1 (mTORC1) inhibitor. Our results showed that lomitapide directly inhibits mTORC1 in vitro and induces autophagy-dependent cancer cell death by decreasing mTOR signaling, thereby inhibiting the downstream events associated with increased LC3 conversion in various cancer cells (e.g., HCT116 colorectal cancer cells) and tumor xenografts. Lomitapide also significantly suppresses the growth and viability along with elevated autophagy in patient-derived colorectal cancer organoids. Furthermore, a combination of lomitapide and immune checkpoint blocking antibodies synergistically inhibits tumor growth in murine MC-38 or B16-F10 pre-clinical syngeneic tumor models. These results elucidates the direct, tumor-relevant immune-potentiating benefits of mTORC1 inhibition by lomitapide, which complement the current immune checkpoint blockade. This study highlights the potential repurposing of lomitapide as a new therapeutic option for cancer treatment.

cancer biology↗

Tumor Landscape Analysis: An Ecologically Informed Framework to Understand Tumor Microenvironments

Tumor microenvironments (TMEs) are spatially complex and dynamic systems shaped by evolutionary pressures, tissue architecture, and cellular interactions. To capture this complexity, we developed the Tumor Landscape Analysis (TLA) pipeline, a computational framework applying principles from landscape ecology and spatial statistics to quantitatively characterize tumor spatial heterogeneity. TLA integrates spatially resolved pathology data, including whole-cell, point-based, and region-level formats, and computes multiscale metrics to assess cell distributions, neighborhood relationships, and tissue-level organization. The framework leverages ecological indices such as the Morisita-Horn index, Ripleys H function, and Shannon diversity to quantify intercellular proximity, spatial clustering, and cellular diversity. It also uses the concept of local microenvironments (LMEs), data-driven ecological niches defined by local cell-type abundance and spatial uniformity, enabling unsupervised and reproducible classification of tumor regions. The use of fragmentation metrics, including patch density, shape complexity, and interspersion, provide further insight into spatial disorganization and emergent tissue architecture. TLA is agnostic to imaging modality and biological context, supporting broad applicability across tumor types and sample formats. By translating complex tissue architectures into interpretable spatial metrics, the pipeline enables integrative analyses that link spatial ecology to clinical and molecular phenotypes. This approach facilitates a deeper understanding of how spatial features contribute to tumor progression, therapeutic resistance, and clinical outcomes, offering new opportunities for precision oncology rooted in spatial systems biology.

cancer biology↗

An oncolytic herpesvirus expressing a CXCR4 antagonist interferes with Glioblastoma cells stemness features and migration.

Glioblastoma is one of the most aggressive brain tumors. Despite the standard therapy, the survival from diagnosis remains dramatically low, especially due to relapses. Considering their capacity to escape the tumor and to migrate to the subventricular zone through a CXCR4-dependant mechanism, Glioblastoma stem-like cells (GSCs) are considered as responsible for these relapses. CXCR4 regulates biological features associated with tumor progression, including self-renewal, migration and radio-resistance. Importantly, its expression correlates with severity and poor prognosis of several cancers including GBM. CXCR4/CXCL12 pathway appears therefore as an interesting potential therapeutic target. We have generated an oncolytic herpesvirus (oHSV) expressing HA-P2G, a mutated form of CXCL12 previously described as a CXCR4 competitive inhibitor. We demonstrate that in vitro, oHSV/P2G impairs human primary GSCs stemness markers expression, self-renewal and migration. In an orthotopic xenograft murine model, its injection within the tumor limits tumor growth and GSCs migration. The ability of P2G to interfere with major GSC features demonstrates the interest in considering oHSV/P2G as a promising new therapeutic approach for glioblastoma patients.

cancer biology↗

Ensemble Feature Selection and Meta-Analysis of Cancer miRNA Biomarkers

The role of microRNAs (miRNAs) in cellular processes captured the attention of many researchers, since their dysregulation is shown to affect the cancer disease landscape by sustaining proliferative signaling, evading program cell death, and inhibiting growth suppressors. Thus, miRNAs have been considered important diagnostic and prognostic biomarkers for several types of tumors. Machine learning algorithms have proven to be able to exploit the information contained in thousands of miRNAs to accurately predict and classify cancer types. Nevertheless, extracting the most relevant miRNA expressions is fundamental to allow human experts to validate and make sense of the results obtained by automatic algorithms. We propose a novel feature selection approach, able to identify the most important miRNAs for tumor classification, based on consensus on feature relevance from high-accuracy classifiers of different typologies. The proposed methodology is tested on a real-world dataset featuring 8,129 patients, 29 different types of tumors, and 1,046 miRNAs per patient, taken from The Cancer Genome Atlas (TCGA) database. A new miRNA signature is suggested, containing the 100 most important oncogenic miRNAs identified by the presented approach. Such a signature is proved to be sufficient to identify all 29 types of cancer considered in the study, with results nearly identical to those obtained using all 1,046 features in the original dataset. Subsequently, a meta-analysis of the medical literature is performed to find references to the most important biomarkers extracted by the methodology. Besides known oncomarkers, 15 new miRNAs previously not ranked as important biomarkers for diagnosis and prognosis in cancer pathologies are uncovered. Such miRNAs, considered relevant by the machine learning algorithms, but still relatively unexplored by specialized literature, could provide further insights in the biology of cancer.

bioinformatics↗

A guide for establishing patient-derived organoids from bile samples obtained during endoscopic procedures and performing gene expression knockdown

Bile represents a clinically accessible biological fluid that can mitigates major limitations associated with tissue-based sampling for the generation of organoid models to study hepatobiliary disease, including biliary tract cancers where tissue availability is often limited. Importantly, bile can also enable the generation of non-malignant cholangiocyte organoids that are otherwise difficult to obtain. Here, we describe an operator-oriented, step-by-step protocol to generate organoids from fresh bile collected during endoscopic retrograde cholangiopancreatography (ERCP), together with two complementary workflows for siRNA delivery in 3D cultures. We detail critical control points that are often under-reported, yet considerably influence success and reproducibility. The protocol was optimized and applied in a real-world cohort of 21 patients undergoing ERCP, including benign biliary obstruction due to choledocholithiasis (n=5) and malignant strictures (n=16: cholangiocarcinoma n=13, gallbladder adenocarcinoma n=1, ampullary tumors n=2). Expandable organoids were established in 17/21 cases (81%), with establishment rates of 60% for choledocholithiasis and 85-100% across malignant entities. Anticipated results include organoid outgrowth within [~]2-3 weeks and morphological heterogeneity in cultures derived from malignant strictures, where normal-like and tumor-like populations may initially coexist and can drift toward a cystic phenotype under routine expansion, motivating optional manual handpicking when tumor-enriched lines are required. As downstream readouts, we show feasibility of DNA-based profiling in selected paired bile-organoid samples (targeted sequencing and ULP-WGS copy-number analysis) and demonstrate proof-of-concept gene silencing via siRNA in both dissociated cells prior to re-embedding, and intact fully formed organoids while preserving 3D architecture. Collectively, this workflow provides a practical and reproducible framework to establish, expand, characterize and functionally perturb bile-derived organoids from routine clinical procedures, facilitating standardized implementation across laboratories.

cancer biology↗

MetScore and classical-basal subtype intersect to define chemotherapy response and tumor microenvironment architecture in pancreatic ductal adenocarcinoma

Background Transcriptomic heterogeneity in pancreatic ductal adenocarcinoma (PDAC) is conventionally modeled along a single classical-basal axis, but this framework incompletely explains clinical behavior. We hypothesized that MetScore, a single-sample measure of metastatic colonization potential, defines a complementary axis. Objective To determine how MetScore and classical-basal identity jointly shape PDAC biology and clinical outcomes. Design We integrated RNA sequencing, DNA sequencing, clinical, and digital pathology data from 512 tumor biopsies from 510 patients in the Pancreatic Cancer Action Network Know Your Tumor real-world cohort. We assessed associations with biopsy site, survival, chemotherapy response, and tumor microenvironment composition; validated metastatic discrimination in an independent cohort; and examined cancer cell-intrinsic drug sensitivity in vitro. Results MetScore distinguished metastatic from primary biopsies, a finding validated externally. High MetScore and basal identity were independently associated with inferior survival. High MetScore and classical identity were each associated with preferential response to 5-fluorouracil (5-FU)-based rather than gemcitabine-based therapy, with the strongest enrichment for 5-FU responses among classical/MetScore-high patients. In vitro drug-sensitivity experiments did not recapitulate the clinical treatment-response pattern, motivating investigation of cancer cell-extrinsic factors. Transcriptomic deconvolution and histopathologic machine learning-based cell annotation demonstrated that high-MetScore and basal states converged on macrophage/monocyte enrichment but diverged in their associations with cancer-associated fibroblasts. Conclusion Integrating MetScore with classical-basal identity establishes a two-axis framework that better explains metastatic behavior, prognosis, treatment response, and microenvironmental composition than the conventional one-axis model and provides a clinically testable strategy for transcriptome-guided patient stratification.

cancer biology↗

Pediatric Sarcoma Data Forms a Unique Cluster Measured via the Earth Mover’s Distance

In this note, we combined pediatric sarcoma data from Columbia University with adult sarcoma data collected from TCGA, in order to see if one can automatically discern a unique pediatric cluster in the combined data set. Using a novel clustering pipeline based on optimal transport theory, this turned out to be the case. The overall methodology may find uses for the classification of data from other biological networking problems.

cancer biology↗

Active monomer RTR-1 derived from the root of Rhodomyrtus tomentosa induces apoptosis in gastric carcinoma cells by inducing ER stress and inhibiting the STAT3 signalling pathway

ObjectiveRhodomyrtus tomentosa, a flowering plant belonging to the Myrtaceae family, is considered an antitumour substance with versatile biological and pharmacological activities. And RTR-1 is an active monomer purified from the root of Rhodomyrtus tomentosa. However, the detail of the mechanisms of anti-cancer activity of RTR-1 remains to be elucidated and the effect on gastric cancer cells is unknown. MethodsCell proliferation was determined by MTT and clone formation assay. The effect of RTR-1 on cell cycle and apoptosis was analyzed utilizing flow cytometry, respectively. Moreover, western blotting was used to detect the expression of cell cycle- and apoptosis-related protein. ResultsBased on MTT and clone formation assay, we noticed that RTR-1 inhibited the proliferation of gastric carcinoma (BGC823 and SGC7901) cells in a dose- and time-dependent manner. Furthermore, the results of flow cytometry and western blotting showed that RTR-1 induced cell cycle arrest in the G2/M phase through the ATM-Chk2-p53-p21 signalling pathway and induced cell apoptosis by inhibiting the signal transducers and activators of transcription 3 (STAT3) pathway and activating the endoplasmic reticulum stress (ER stress) pathway. ConclusionTaken together, these results demonstrate that RTR-1 induces cell cycle arrest and promotes apoptosis in gastric carcinoma, indicating its potential application for gastric cancer therapy.

cancer biology↗

Inhibition of serotonin biosynthesis in neuroendocrine neoplasm suppressestumor growth in vivo

Small bowel neuroendocrine tumors (SBNETs) originate from enterochromaffin cells in the intestine which synthesize and secrete serotonin. SBNETs express high levels of tryptophan hydroxylase 1 (Tph1), a key enzyme in serotonin biosynthesis. Patients with high serotonin level may develop carcinoid syndrome, which can be treated with somatostatin analogues and the Tph1 inhibitor telotristat ethyl in severe cases. Although the active drug telotristat can efficiently reduce serotonin levels, its effect on tumor growth is unclear. This study determined the effect of serotonin inhibition on tumor cell growth in vitro and in vivo. The levels of Tph1 in various neuroendocrine neoplasms (NENs) were determined and the biological effects of Tph1 inhibition in vitro and in vivo using genetic and pharmacologic approaches was tested. Gene and protein expression analyses were performed on patient tumors and cancer cell lines. shRNAs targeting TPH1 were used to create stable knockdown in BON cells. Control and knockdown lines were assessed for their growth rates in vitro and in vivo, angiogenesis potential, serotonin levels, endothelial cell tube formation, tumor weight, and tumor vascularity. TPH1 is highly expressed in SBNETs and many cancer types. TPH1 knockdown cells and telotristat treated cells showed similar growth rates as control cells in vitro. However, TPH1 knockdown cells formed smaller tumors in vivo and tumors were less vascularized. Although Tph1 inhibition with telotristat showed no effect on tumor cell growth in vitro, Tph1 inhibition reduced tumor formation in vivo. Serotonin inhibition in combination with other therapies is a promising new avenue for targeting metabolic vulnerabilities in NENs.

cancer biology↗

Receptor Tyrosine Kinase Profiling Identifies Chronic Constitutive Floodgate Oxidative Signaling in Glutathione-Independent Human Mammary Luminal Progenitor Cells

The human mammary epithelium contains a subset of luminal progenitor (LP) cells that are distinct from basal cells in both lineage potential and redox biology. LPs are uniquely equipped to tolerate oxidative stress through glutathione-independent mechanisms and have been implicated as candidate cells of origin in basal-like breast cancers. In this study, we identify the receptor tyrosine kinase (RTK) cKIT (CD117), as a defining feature of LPs and a key mediator of their expansion. cKIT is developmentally restricted to the LP compartment via Polycomb-mediated epigenetic repression in basal and luminal-committed cells. It is expressed in scattered epithelial cells within both ductal and alveolar regions of resting human mammary glands. Using RTK-engineered MCF10A models, we demonstrate that cKIT ligand/stem cell factor (SCF)-activated wildtype cKIT signaling is sufficient to drive proliferation in the absence of epidermal growth factor (EGF) and that cKIT is responsive not only to canonical ligands but also to hydrogen peroxide (H2O2). In primary human LPs, cKIT is rapidly phosphorylated upon exposure to SCF and H2O2, with concomitant AKT activation. These responses are enhanced when cKIT and EGFR signaling are co-engaged, suggesting a cooperative mitogenic program. In mammary gland, phosphorylation of the antioxidant enzyme PRDX1 is selectively detected in LPs, consistent with a floodgate model of redox signaling in which transient oxidative inactivation of peroxiredoxins (PRDXs) facilitates RTK signaling under elevated intracellular reactive oxygen species conditions. Clinically, elevated cKIT expression is associated with shorter progression-free survival in certain basal-like breast cancer, supporting a link between LP-like redox signaling states and aggressive tumor behavior. Together, these findings define a redox-integrated RTK signaling axis centered on cKIT that drives LP expansion and is associated with poor outcomes in a subset of basal breast cancers. This work establishes a mechanistic framework for targeting redox-responsive progenitor populations in both regenerative and oncologic context.

cancer biology↗

No effect of administration of unacylated ghrelin on subcutaneous PC3 xenograft growth in a Rag1-/- mouse model of metabolic dysfunction

Ghrelin is a peptide hormone which, when acylated, regulates appetite, energy balance and a range of other biological processes. Ghrelin predominately circulates in its unacylated form (unacylated ghrelin; UAG). UAG has a number of functions independent of acylated ghrelin, including modulation of metabolic parameters and cancer progression. UAG has also been postulated to antagonise some of the metabolic effects of acyl-ghrelin, including its effects on glucose and insulin regulation. In this study, Rag1-/- mice with high-fat diet-induced obesity and hyperinsulinaemia were subcutaneously implanted with PC3 prostate cancer xenografts to investigate the effect of UAG treatment on metabolic parameters and xenograft growth. Daily intraperitoneal injection of 100 g/kg UAG had no effect on xenograft tumour growth in mice fed normal rodent chow or 23% high-fat diet. UAG significantly improved glucose tolerance in host Rag1-/- mice on a high-fat diet, but did not significantly improve other metabolic parameters. We hypothesise that UAG is not likely to be an effective treatment for prostate cancer, with or without associated metabolic syndrome.\n\nConflict of interestThe authors declare no conflict of interest.

cancer biology↗

Sanguinarine activates ATM/ATR-mediated CHK-1 signaling to drive p53-dependent apoptosis in the C. elegans germline

Sanguinarine (SNG) is a natural component belonging to the benzophenanthridine alkaloids. In recent years, due to its remarkable biological activities, it has gained wide interest in the pharmaceutical industry. Various studies have reported its potential as a therapeutic agent in treating chronic human diseases such as cancer. SNG is widely reported to cause programmed cell death in various cancer cell lines. The mechanism by which SNG triggers apoptosis remains poorly elucidated, especially in vivo. Previous studies reported that sanguinarine induces apoptosis by increasing reactive oxygen species (ROS). In this study, we aimed to characterize the effects of SNG using an in vivo Caenorhabditis elegans (C. elegans) model. Treating C. elegans with various SNG concentrations resulted in apoptotic cell death in the proliferative germline. Interestingly, SNG-induced apoptosis depends on the core apoptotic machinery initiated by the DNA-damage-induced activity of the p53/CEP-1 protein. We have also demonstrated that the increase in germ cell apoptosis is caused by elevated levels of reactive oxygen species (ROS) following SNG treatment. Notably, the apoptotic phenotype induced by SNG was resolved upon treatment with the ROS scavenger. Altogether, our study demonstrates that SNG increases ROS, leading to activation of DNA damage-induced apoptosis in the proliferative germline of C. elegans.

cancer biology↗

Cancer classification in the genomic era: five contemporary problems

Classification is an everyday instinct as well as a full-fledged scientific discipline. Throughout the history of medicine, disease classification is central to how we develop knowledge, make diagnosis, and assign treatment. Here we discuss the classification of cancer, the process of categorizing cancer subtypes based on their observed clinical and biological features. Traditionally, cancer nomenclature is primarily based on organ location, e.g., \"lung cancer\" designates a tumor originating in lung structures. Within each organ-specific major type, finer subgroups can be defined based on patient age, cell type, histological grades, and sometimes molecular markers, e.g., hormonal receptor status in breast cancer, or microsatellite instability in colorectal cancer. In the past 15+ years, high-throughput technologies have generated rich new data regarding somatic variations in DNA, RNA, protein, or epigenomic features for many cancers. These data, collected for increasingly large tumor collections, have provided not only new insights into the biological diversity of human cancers, but also exciting opportunities to discover previously unrecognized cancer subtypes. Meanwhile, the unprecedented volume and complexity of these data pose significant challenges for biostatisticians, cancer biologists, and clinicians alike. Here we review five related issues that represent contemporary problems in cancer taxonomy and interpretation. 1. How many cancer subtypes are there? 2. How can we evaluate the robustness of a new classification system? 3. How are classification systems affected by intratumor heterogeneity and tumor evolution? 4. How should we interpret cancer subtypes? 5. Can multiple classification systems coexist? While related issues have existed for a long time, we will focus on those aspects that have been magnified by the recent influx of complex multi-omics data. Ongoing exploration of these problems is essential for data-driven refinement of cancer classification and the successful application of these concepts in precision medicine.

Genomics↗

Subtype-specific Patterns of Evolution and Clinically Relevant Genomic Instability in Wilms Tumour

BackgroundUnderstanding cancer evolution is fundamental to predicting cancer progression. However, the evolution of paediatric cancers is still under-researched. Large cohorts of patients are required to determine consistent evolutionary trajectories that shed light on key steps in cancer development and reveal underlying biology, especially in rare cancers. Additionally, well annotated clinical data is necessary for determining if evolutionary biomarkers are predictive of patient outcome. MethodsWe performed detailed evolutionary analysis of 64 paediatric kidney cancers, including 60 Wilms tumours (WT), using DNA microarrays and, in a subset of 30 patients, a WT-specific targeted sequencing assay, to detect copy number alterations (CNA) and mutations, respectively. By analysing multiple tissue samples in the majority of cases we could detect mutation heterogeneity in each tumour. We reconstructed clones across the cohort and described their phylogenetic histories, in addition to detecting mirrored subclonal allelic imbalance. ResultsOur results highlight pervasive evidence of parallel evolution in WTs affecting CNAs, and CTNNB1 and TP53 mutations. Furthermore, we demonstrate that stromal-type WTs often evolve from a consistent series of events (WT1 mutation, 11p uniparental disomy and CTNNB1 mutation) and we suggest that 19q uniparental disomy is an important ancestral event in both epithelial and diffuse anaplastic WTs. Finally, we propose the total number of evolutionary CNA events as a prognostic biomarker in WTs for event-free survival, particularly in high-risk WT. ConclusionsOverall, this study sheds light on the evolution of the most common paediatric kidney cancer and links evolutionary analysis to fundamental clinical and biological questions in a large cohort of WTs. We conclude that histological subtypes of WT are often defined by consistent evolutionary sequences. We present evidence that a key marker of evolvability, namely CNA diversity measured phylogenetically across multiple tumour sites, is prognostic of patient outcome and should be considered for clinical use to detect the most aggressive blastemal and diffuse anaplastic type WTs.

cancer biology↗

siRNA Mediated Genetic Perturbation of Primary Human Leukemia Stem and Progenitor Cells

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are aggressive hematologic malignancies with poor outcomes. Leukemia stem and progenitor cells (LSPCs) are a subset of cells within the bulk tumor thought to be responsible for initiating disease and causing relapse. LSPCs evade chemotherapy partially due to their quiescent state. Therefore, studying this cell subpopulation is critical to identify new disease targets that can better the outcomes of AML/MDS patients. The use of RNAi and genetic approaches is technically challenging in primary leukemia cells and particularly LSPCs. Overcoming this technical hurdle could greatly expand the breath of pre-clinical and mechanistic examination of LSPCs. In this study, we describe a methodology to efficiently introduce siRNA, resulting in effective gene knock down in LSPCs. After isolation of LSPCs from primary patient samples, we showed that electroporation of these cells does not affect cell viability significantly. Further, using siGLO green transfection indicator, we show that RNA is introduced into the nucleus of these cells. siRNA transfection leads to efficient knockdown of target genes and has subsequent biological relevant activity. We have identified a method to effectively knock down genes in leukemia stem and progenitor cells, opening up new avenues to examine LSPC biology in human specimens.

cancer biology↗

Transcriptomic atlas of premalignant oral squamous cell carcinoma in an aging mouse model reveals an enhanced immune response and dysregulation of head and neck tissue stem cells

Oral squamous cell carcinomas (OSCC) account for [~]90% of all oral malignancies and have devastating effects on overall health and quality of life. However, little is known about the early initiating events that drive the development of oral leukoplakia-like premalignant lesions (OPLs) and disease progression. Here, we create a mouse model of tobacco-related premalignant OSCC that takes into consideration its primary risk factors, including advancing age and male sex. This model notably recapitulates the age variant patterns of OSCC risk observed in humans, with a higher prevalence of oral premalignant lesions in older mice. In addition, by building a transcriptomic atlas with this system, we reveal genetic signatures associated with oncogenic progression in the tongue and buccal epithelium, and their resident somatic tissue stem cells. We also identify several novel transcriptomic signatures of premalignancy in OSCC, including enhanced immune response and expansion and dysregulation of head and neck tissue stem cells. These findings offer a new framework for investigating physiologically-relevant risk factors and drivers of OSCC and illuminate novel biological pathways underlying its pathology.

cancer biology↗